

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Advisory Committee (DAC)

### Minutes of the meeting on Wednesday 17 August 2016

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

#### **PRESENT:**

##### **Standing Committee members:**

Dr Mark Kroese (Chair)  
Mrs Alexandria Moseley  
Professor Anthony Wierzbicki  
Professor Christopher Hyde  
Dr Dermot Neely  
Dr Jim Gray  
Mr John Bagshaw  
Mr John Hitchman  
Mr Patrick McGinley  
Dr Phil Chambers  
Dr Simon Richards  
Dr Steve Edwards  
Dr Sue Crawford

##### **Standing Committee apologies:**

Professor Adrian Newland  
Dr Deirdre Ryan  
Professor Erika Denton  
Professor Mark Sculpher  
Dr Michael Messenger  
Dr Peter Naylor  
Professor Ron Akehurst  
Dr Simon Fleming  
Dr Steve Thomas

##### **NICE staff in attendance:**

Mirella Marlow, Programme Director, DAP  
Carla Deakin, Associate Director, DAP  
Frances Nixon, (Technical lead) Technical Analyst, DAP  
Rebecca Albrow, Technical Adviser, DAP  
Robert Fernley, Project Manager, DAP  
Christopher Pomfrett, Technical Adviser, MTEP

**Observing:**

Amanda Chandler, Project Manager, NICE  
Elaine Chesworth, Medical Technology Implementation Manager  
Jane Lynn, Business Analyst, NICE  
Jessica Maloney, Technical Analyst NICE  
Linda Grainger, Senior Medical Editor, NICE  
Thomas Walker, Technical Analyst, NICE

**1. Introduction to the meeting**

The Chair welcomed Committee members, observers and members of the public.  
Apologies were noted.

**2. Code of conduct for members of the public attending the meeting**

The Chair explained the code of conduct to the members of the public attending this meeting.

**3. Any other business**

No other business was offered.

**4. Minutes from the last Committee meeting**

The Committee agreed the minutes from the 20 July 2016 Committee meeting.

**5. NICE's advisory body guide to declaring a conflict of interest**

The Chair drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

**High-throughput non invasive prenatal testing for fetal RHD genotype**

**External Assessment Group representatives: Centre for Reviews and Dissemination(CRD)/Centre for Health Economics (CHE), University of York**

Mark Simmonds, Research Fellow  
Susan Griffin, Senior Research Fellow

**Specialist Committee members:**

Dr Alec McEwan, Consultant Obstetrician and Subspecialist in Fetal Medicine, Nottingham University Hospitals NHS Trust  
Ms Jenny Ford, Midwifery Matron, University Hospitals Bristol NHSFT  
Mrs Jo Davis, Senior Antenatal Screening Scientist, Nottingham University Hospitals NHS Trust  
Dr Ruth Gottstein, Consultant Neonatologist, St Mary's Hospital  
Dr Samantha Revill, Lay specialist committee member  
Dr Sue Robinson, Consultant Haematologist, Guy's and St Thomas' NHSFT

**Specialist Committee members apologies:**

None

**PART 1 AND PART 2 (open and closed parts of the meeting).**

**Part 1 – Open session**

The Chair welcomed representatives from the International Blood Group Reference Laboratory.

There were no public attendees.

The Chair asked Committee members to declare any relevant interests.

- Dr Mark Kroese declared a personal non-specific financial interest; this interest did not preclude him from taking part in the meeting.

The Committee proceeded to discuss the comments made during the public consultation for high-throughput non invasive prenatal testing for fetal RHD genotype.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance, participation and contribution to the meeting.

**End of Part 1**

**Part 2 – closed session**

Agreement on the content of the Diagnostics Guidance Document (DGD) was discussed by the committee.

**End of Part 2**

**Date, time and venue of next meeting**

Tuesday 20 September 2016 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD